Log in

NASDAQ:BMRN - BioMarin Pharmaceutical Stock Price, Forecast & News

$89.01
+0.77 (+0.87 %)
(As of 02/17/2020 02:09 AM ET)
Add
Today's Range
$87.28
Now: $89.01
$89.10
50-Day Range
$83.50
MA: $86.60
$91.10
52-Week Range
$62.88
Now: $89.01
$96.20
Volume766,625 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:BMRN
CUSIP09061G10
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees2,849
Next Earnings Date2/26/2020 (Confirmed)
OptionableOptionable

Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.


BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) posted its quarterly earnings results on Wednesday, October, 23rd. The biotechnology company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.06 by $0.25. The biotechnology company had revenue of $461.10 million for the quarter, compared to analyst estimates of $455.78 million. The firm's quarterly revenue was up 17.7% compared to the same quarter last year. During the same period last year, the company posted ($0.07) earnings per share. View BioMarin Pharmaceutical's Earnings History.

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for BioMarin Pharmaceutical.

How can I listen to BioMarin Pharmaceutical's earnings call?

BioMarin Pharmaceutical will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for BMRN?

16 brokers have issued 12 month price targets for BioMarin Pharmaceutical's shares. Their forecasts range from $77.00 to $158.00. On average, they expect BioMarin Pharmaceutical's share price to reach $111.41 in the next year. This suggests a possible upside of 25.2% from the stock's current price. View Analyst Price Targets for BioMarin Pharmaceutical.

What is the consensus analysts' recommendation for BioMarin Pharmaceutical?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioMarin Pharmaceutical.

What are Wall Street analysts saying about BioMarin Pharmaceutical stock?

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:
  • 1. According to Zacks Investment Research, "BioMarin’s key orphan disease drugs — Vimizim and Kuvan — continue to do well, driven by strong demand trends. Its newest product, Palynziq is witnessing strong commercial uptake in the United States. BioMarin’s rare disease pipeline is also progressing well. The company filed regulatory applications for Valrox in late 2019 and targets the same for vosoritide in 2020. Growing pipeline focus on gene therapy agents is encouraging. Valrox, a gene therapy for hemophilia A, is anticipated to be transformational, if approved. However, any development setbacks related to its pipeline candidates can hurt the stock. Moreover, uneven quarterly product sales of Naglazyme and Vimzin, owing to infrequent ordering patterns in some ex-U.S. countries, are a concern. The stock has underperformed the industry in the past one year.<" (1/15/2020)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our OW and $131 PT. We continue to see highly favorable risk/reward ahead of key pipeline updates over the next 12 months. BioMarin reported an in-line quarter, although the overwhelming focus of the call was on valrox (hemophilia A gene therapy). The valrox 3-year update is on track for a top-line by early June (ISTH late-breaker submission due June 7). Not much new color on valrox from the call: management continues to sound confident in durability and potential for accelerated pathway (BMRN’s filing decision by YE19). For investors, we think valrox is more of a show-me story, which is why the update in June is important, although at this point somewhat of an overhang, in our view." (4/26/2019)

Has BioMarin Pharmaceutical been receiving favorable news coverage?

News headlines about BMRN stock have trended somewhat positive on Monday, according to InfoTrie. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioMarin Pharmaceutical earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for BioMarin Pharmaceutical.

Are investors shorting BioMarin Pharmaceutical?

BioMarin Pharmaceutical saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 8,700,000 shares, an increase of 14.3% from the December 31st total of 7,610,000 shares. Based on an average daily volume of 1,440,000 shares, the days-to-cover ratio is presently 6.0 days. Currently, 4.9% of the company's stock are short sold. View BioMarin Pharmaceutical's Current Options Chain.

Who are some of BioMarin Pharmaceutical's key competitors?

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Celgene (CELG), Array Biopharma (ARRY) and Freeport-McMoRan (FCX).

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the folowing people:
  • Mr. Jean-Jacques Bienaimé M.B.A., MBA, Chairman & CEO (Age 66)
  • Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 60)
  • Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 64)
  • Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 57)
  • Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 61)

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include UBS Asset Management Americas Inc. (0.75%), USS Investment Management Ltd (0.66%), Manning & Napier Group LLC (0.61%), First Trust Advisors LP (0.48%), Pictet Asset Management Ltd. (0.42%) and TCW Group Inc. (0.41%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.

Which major investors are selling BioMarin Pharmaceutical stock?

BMRN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, DekaBank Deutsche Girozentrale, Torray LLC, Rhenman & Partners Asset Management AB, Bank of Montreal Can, Rafferty Asset Management LLC, CNH Partners LLC and TCW Group Inc.. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical.

Which major investors are buying BioMarin Pharmaceutical stock?

BMRN stock was purchased by a variety of institutional investors in the last quarter, including USS Investment Management Ltd, Manning & Napier Group LLC, Sofinnova Investments Inc., Scout Investments Inc., Marshall Wace LLP, Point72 Asset Management L.P., UBS Asset Management Americas Inc. and Samlyn Capital LLC. View Insider Buying and Selling for BioMarin Pharmaceutical.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $89.01.


MarketBeat Community Rating for BioMarin Pharmaceutical (NASDAQ BMRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,370 (Vote Outperform)
Underperform Votes:  817 (Vote Underperform)
Total Votes:  2,187
MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe BMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel